Who is sponsoring NCT04822389?

NCT04822389 is sponsored by Brno University Hospital.

What drugs are being tested in NCT04822389?

Interventions in NCT04822389: Telerehablitation using heart rate monitor.

What condition does NCT04822389 study?

NCT04822389 studies Lymphoma, Rehabilitation.

Is NCT04822389 still recruiting?

NCT04822389 is currently completed. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT04822389

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Telerehabilitation and Lymphoma Patients

Completed NA Last updated 20 July 2022

What this trial tests

NA trial testing Telerehablitation using heart rate monitor in Lymphoma in 15 participants. Completed in 31 May 2022.

Timeline

1 April 2021

Primary endpoint
26 April 2022

31 May 2022

Quick facts

Lead sponsor	Brno University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	15
Start date	1 April 2021
Primary completion	26 April 2022
Estimated completion	31 May 2022
Sites	1 location across Czechia

Drugs / interventions tested

Telerehablitation using heart rate monitor

Conditions studied

Lymphoma — all drugs for Lymphoma →
Rehabilitation — all drugs for Rehabilitation →

Sponsor

Brno University Hospital

Who can join

18 and older, any sex, with Lymphoma or Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to examine the feasibility and effect of a home-based short-term telerehabilitation exercise intervention using heart rate monitor and internet platform in patients with lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Home-based cardio-oncology rehabilitation using a telerehabilitation platform in hematological cancer survivors: a feasibility study.
Filakova K, Janikova A, Felsoci M, Dosbaba F, et al · · 2023 · cited 15× · PMID 36959613 · DOI 10.1186/s13102-023-00650-2

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Brno University Hospital trials

Trials by the same sponsor.

NCT07468006 — Comparison of Transcutaneous and Blood CO₂ Measurement in Critically Ill Children · recruiting
NCT07280039 — Mortality and Muscle Mass Loss in Critically Ill Patients. · not yet recruiting
NCT07279701 — The Effect of Near-infrared Spectroscopy on the Success of Peripheral Venous Access · NA · recruiting
NCT07245654 — Monitoring the Depth of Anesthesia and Nociception During the Induction of General Anesthesia in Pediatric Patients · recruiting
NCT07110012 — The Role of Simulation-based Training in Resident Curriculum in Anaesthesia and Intensive Care · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04822389 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brno University Hospital
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing